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INTRODUCTION
Fragile X syndrome (FXS) is the most common cause of
inherited mental retardation and the second most common
cause of genetically associated mental retardation following
trisomy 21 (1). FXS is caused by a dynamic mutation which
involves an unstable expansion of a trinucleotide CGG repeat
at the 5′ -untranslated region (UTR) of the fragile X mental
retardation 1 (FMR1) gene, located at Xq27.3. The silenc-
ing of the FMR1 gene leads to the deficiency of the fragile
X mental retardation protein (FMRP), thus causing the clas-
sical FXS. The population-based prevalence study of full
mutation (CGG≥200 repeats and cytosine methylation) of
FMR1 through DNA analysis was estimated 1/4,000 males
and 1 in 8,000 females. Furthermore, there have been grow-
ing evidences of premutation (55-200 CGG repeats)-associ-
ated clinical phenotypes such as milder forms of FXS includ-
ing autistic features, developmental delay and latter pheno-
types of fragile X tremor ataxia syndrome, and premature
ovarian failure. Considering the prevalence of full mutation
and premutation as well as their consequences on children’s
development and their latter phenotypes, the impact of FXS
is thought to be much more enormous than what has earlier
been thought.
There have been growing interests worldwide on the molec-
ular diagnosis and clinical experiences on FXS. At present,
polymerase chain reaction (PCR) (2), methylation-specific
PCR (MS-PCR) (3), and Southern blotting (4) are considered
as the golden standard for the diagnosis of FXS. Several lab-
oratories in South Korea recently embarked on the molecu-
lar studies of FXS, thus allowing much experience on FXS. 
To the best of our knowledge, reports on FXS in Korea
had been relatively few, compared to those of western coun-
tries. Furthermore, there has been no report that MS-PCR
was used for the diagnosis of FXS in Korea. The purposes of
this study were to present DNA analysis findings of our case
series of FXS based on MS-PCR, PCR, and Southern blot-
ting alongside developmental characteristics including psy-
chological profiles and to review the literature on FXS in
Korea. 
MATERIALS AND METHODS
Case series 
During the period of 26 months from March 2004 to
May 2006, the DNA samples of 65 children (male:female,
52:13; age, 6.12±4.00 yr-old) were received at the Depart-
ment of Medical Genetics, Ajou University Medical Center
470
Shin-Young Yim, Bo Hyun Jeon, 
Jung A Yang*, and Hyon J. Kim*
Department of Physical Medicine and Rehabilitation,
Department of Medical Genetics*, Ajou University
School of Medicine, Suwon, Korea
Address for correspondence
Hyon J. Kim, M.D.
Department of Medical Genetics, Ajou University
School of Medicine, San 5 Woncheon-dong, 
Youngtong-gu, Suwon 442-721, Korea
Tel : +82.31-219-5903, Fax : +82.31-219-5299
E-mail : genetics@kornet.net
J Korean Med Sci 2008; 23: 470-6
ISSN 1011-8934
DOI: 10.3346/jkms.2008.23.3.470
Copyright � The Korean Academy
of Medical Sciences
Fragile X Syndrome in Korea: A Case Series and a Review of the Literature
The purposes of this study were to present DNA analysis findings of our case series
of fragile X syndrome (FXS) based on methylation-specific polymerase chain reac-
tion (MS-PCR), PCR, and Southern blotting alongside developmental characteris-
tics including psychological profiles and to review the literature on FXS in Korea.
The reports of 65 children (male:female, 52:13; age, 6.12± ±4.00 yrs) referred for
the diagnosis of FXS over a 26-months period were retrospectively reviewed for
the identification of full mutation or premutation of fragile X mental retardation 1
(FMR1). Among the 65 children, there were 4 boys with full mutation, and one boy
showed premutation of FMR1, yielding a 6.15% positive rate of FXS. All 4 children
with full mutation showed significant developmental delay, cognitive dysfunction,
and varying degrees of autistic behaviors. The boys with premutation showed also
moderate mental retardation, severe drooling, and behavioral problems as severe
as the boys with full mutation. Thirteen articles on FXS in Korea have been pub-
lished since 1993, and they were reviewed. The positive rate of FXS was in the
range of 0.77-8.51%, depending on the study groups and the method of diagno-
sis. Finally, the population-based prevalence study on FXS in Korea is required in
the near future. 
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for the diagnosis of FXS. The main problems suggestive of
FXS were developmental delay, cognitive dysfunction, and
behavioral problems.
The reports of these 65 cases were reviewed in order to
identify either full mutation or premutation of FMR1. Full
mutation for boys was diagnosed by the presence of methy-
lated CpG island in the promoter of the FMR1 as well as
the presence of large expansions (≥200) of CGG repeats of
FMR1 on the MS-PCR, PCR, and Southern blotting. Pre-
mutation of FMR1 for boys was diagnosed by the presence
of 55-200 repeats of CGG in FMR1 and unmethylated CpG
island on the MS-PCR, PCR, and Southern blotting. For girls,
the status of full mutation or premutation of FMR1 was deter-
mined according to the results of PCR and Southern blot-
ting for FMR1. It was based on the definition by American
College of Medical Genetics in 2001 where the lower bound
of the premutation range was 55 CGG repeats, irrespective
of the nucleotide composition of the repeat sequence (5).
The phenotypic characteristics, such as age at diagnosis of
FXS, gender, developmental characteristics, the presence of
dysmorphic features, and brain MRI findings, were collect-
ed through a retrospective review of the medical charts of
the children with full mutation or premutation of FMR1. 
The MS-PCR, PCR, and Southern blotting were used for
FMR1, and the laboratory procedures were as follows.
Methylation-specific PCR analysis
The genomic DNA was extracted by the EZ DNA methy-
lation kit (Zymo Research, Orange, CA, U.S.A.). For PCR
amplification of the CpG island located upstream of the
repeats, the following primers were used: FR690F: 5′ -AAC
GAC GAA CCG ACG ACG-3′ and FR611R: 5′ -CGT CGT
CGC GTT GTC GTAC-3′ . The primers were designed for
the modified antisense strand and were specific for the ampli-
fication of the methylated C present in affected males and
in the normal female FMR1 gene on the inactive X chro-
mosome. PCR was modified and carried out as described
previously (3).
PCR amplification for CGG expansion region of FMR1
Using the FXS kit (Abbott Laboratories, Abbott Park, IL,
U.S.A.), amplification of the CGG repeat region of normal
and premutated alleles in the FMR1 gene was carried out
by PCR with a total volume of 10 μ L, containing 20 ng of
genomic DNA according to the manufacturer’s protocols.
The PCR-amplified products were resolved by electrophore-
sis on 1.5% agarose gels. To establish the fragment sizes of
these products, the ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA, U.S.A.) was used.
The Genescan software (Applied Biosystems) was used for
accurate size calling and quantification of peak areas. The
repeat number of CGG of FMR1 that could be analyzed by
the ABI PRISM 3100 Genetic Analyzer was up to 230 re-
peats, whereas the electrophoresis on 1.5% agarose gels was
used to identify 230-900 repeats of CGG of FMR1. 
Southern blot analysis
Total genomic DNA was extracted from peripheral blood
leukocytes by the salt-precipitation method, using Pure-
gene kits (Gentra Systems, Inc., Minneapolis, MN, U.S.A.)
and stored in a buffer, containing 10 mM Tris-HCl and 1
mM disodium EDTA, pH 8.0, at 4℃. Genomic DNA (15
μ g) was digested with both EcoR I (100 U; New England
Biolabs, Ipswich, MA, U.S.A.), and methylation-sensitive
enzyme Eag I (50 U; New England Biolabs). Procedures
were carried out, according to the procedures described in
the Biotin Luminescent Detection kit (Kirkegaard & Perry
Laboratories, Inc., Gaithersburg, MD, U.S.A.) (4).
Review of the literature
The PubMed database (January 1969 to January 2007)
and the KoreaMed (http://www.koreamed.org/SearchBa-
sic.php; January 1969 to January 2007) were searched to
identify Korean reports on FXS with the key words, FXS
and Korea.  
RESULTS
Case series
Among 65 children, who were referred for the evaluation
of developmental delay, cognitive dysfunction, and behavioral
problems, there were 4 boys with full mutation and one boy
with premutation of FMR1. Table 1 shows the findings of
molecular studies and clinical characteristics for 5 boys. Bas-
ed on DNA analysis, this yielded a 6.15% positive rate of
full mutation of FMR1. The mean age at the diagnosis of
full mutation or premutation of FMR1 was 4.28 yr (range,
1.2-9.9 yr old). Four boys (case 1-4) showed methylated sta-
tus in the CpG island of the FMR1 and had 200 or more
CGG repeats of FMR1 (Fig. 1). Case 1 showed methylated
status on the MS-PCR. The PCR using ABI PRISM 3100
Genetic Analyzer and Genescan did not show any peak,
which indicated more than 230 repeats of CGG. The elec-
trophoresis using 1.5% agarose gels showed full mutation
in the range of 200-900. Although Southern blotting could
not be done, because there was not enough DNA sample
left for the procedure, these findings indicated that case 1
had full mutation of FMR1 with methylation. Case 5 did
not show methylation on the MS-PCR, and the PCR analy-
sis using ABI PRISM 3100 Genetic Analyzer and Genescan
showed 58 repeats of CGG of FMR1, which indicated pre-
mutation according to our operant definition in which pre-
mutation of FMR1 for boys was diagnosed by the presence
of 55-200 repeats of CGG in FMR1 and unmethylated CpG
island. 472 S.-Y. Yim, B.H. Jeon, J.A. Yang, et al.
Among the 5 cases, the mothers in 4 cases (case 1, 2, 3
and 5) also underwent PCR for FMR1, and the findings are
shown in Table 1. The mother of case 1 showed full muta-
tion (29/≥200) of FMR1. Case 2 who showed full muta-
tion of FMR1 had his mother with premutation (43/108
repeats of CGG) of FMR1. His maternal grandmother had
normal-sized alleles (28/43 repeats of CGG; Fig. 1-[2]-lane
7), therefore, the premutated FMR1 of the mother of case 2
could be transmitted from her father who had died from a
motor vehicle accident 10 yr ago. The premutated FMR1 of
the mother was transmitted to her son (case 2), which expand-
ed to full mutation of FMR1. Case 3 with full mutation of
FMR1 had the mother with premutation (33/82 repeats of
CGG). The mother of case 5 who had premutation of FMR1
(58 repeats of CGG) showed premutation (28/ 56 repeats of
CGG) of FMR1.
The clinical characteristics of 4 boys with FXS and the boy
with premutation of FMR1 are shown in Table 1. As shown
in the table, they all revealed significant cognitive dysfunc-
tion. Their birth weight and gestational period were within
the normal range (3,290±625 g; 38.6±1.34 weeks). Some
dysmorphic features were recognized such as large ears, pes
planovalgus, high arched palate, macroglossia, and large
hands with plenty of palmar creases. Five children all showed
varying degrees of autistic behaviors and significant delay in
language development. Brain MRI did not show remark-
able structural abnormalities in all 5 cases. The boy with
premutation (case 5) showed moderate mental retardation
with SQ 48.4, severe drooling, microcephaly, short atten-
tion span, and gaze avoidance. 
Case
Sex/
age (yr)
MS-PCR PCR
Southern
blotting
Interpretation
PCR findings 
of maternal
FMR1
Psychological
evaluation
Brain 
MRI
Birth weight (g)/
gestational period
(week)
1 M/1.2 Methylated ≥230 Not done Full mutation 29/≥230 4,250/38 MDI<50 NL
PDI<50 
2 M/1.9 Methylated ≥230 ≥200 Full mutation 43/108 2,900/38 MDI<50 NL
PDI<50
3 M/4.8 Methylated ≥230 ≥200 Full mutation 33/82 3,300/37 VIQ 61/PIQ 63 NL
4 M/9.9 Methylated ≥230 Not done Full mutation Not done 3,400/40 IQ: failed NL
SQ 41.4
5 M/4.1 Unmethylated 58 50-200 Premutation 28/56 2,600/40 MDI<50   NL
PDI<50
Table 1. The molecular diagnostic findings and clinical characteristics of the cases with full mutation or premutation of FMR1
MS-PCR, methylation-specific polymerase chain reaction; MDI PDI, the mental and psychomotor developmental indices of the Bayley scales of infant
development-II; VIQ, verbal intelligence quotient; PIQ, performance intelligence quotient; SQ, social quotient; NL, normal findings.
A
Fig. 1. The molecular diagnostic findings of fragile X syndrome.
1 234 56 7
Lane 1, Normal female
Lane 2, Normal male
Lanes 3-6, Cases 1-4 with full mutation of FMR1
Lane 7, Case 5 with premutation of FMR1
Land 1, Normal female
Land 2, Normal male
Lane 3, Case 1 with full mutation of FMR1 (≥200)
Lane 4, The mother of case 1 with full mutation of FMR1 (29/≥200)
Lane 5, Case 2 with full mutation of FMR1 (≥200)
Lane 6, The mother of case 2 with premutation of FMR1 (43/108)
Lane 7, The grandmother of case 2 with normal-sized alleles of FMR1 (28/43)
Lane 8, Case 3 with full mutation of FMR1 (≥200)
Lane 9, The mother of case 3 with full premutation of FMR1 (33/82)
Lane 10, Case 4 with full mutation of FMR1 (≥200)
Lane 11, Case 5 with premutation of FMR1 (58)
Lane 12, The mother of case 5 with premutation of FMR1 (28/56)
The MS-PCR findings of FMR1
B
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≥200 repearts 
(full mutation)
3,000
bp
1,000
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(premutation)
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The PCR findings of FMR1
5.2 kb
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123 4 56 7
Lane 1, Normal male
Lane 2, Normal female
Lane 3, Case 5 with premutation of 
FMR1 (58)
Lane 4, The mother of case 5 with 
premutation of FMR1 (28/56)
The Southern blotting fingdings of case 5 with premutation
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Review of the literature
Thirteen articles on FXS published in Korea since 1993
were reviewed (6-18) and its summary is presented in Table
2. The positive rate of FXS was in the range of 0.77-8.51%,
depending on the study groups and the method of diagnosis
(6, 8, 9, 11, 13-15, 17) The prevalence survey for 699 neonates
showed 0.43% of premutation of FMR1 (16). There was a
case report of prenatal diagnosis for the fetus from the mother
of known premutation of FMR1, which showed that the
fetus had full mutation of FMR1 (12). Song et al. reported
the mean CGG repeat number (26.9 repeats) of FMR1 in
Korean women (18), and Hur et al. detected premutation of
FMR1 in 3.6% of women with idiopathic premature ovari-
an failure (10). 
DISCUSSION
Here, we presented our case series of FXS with a review of
the Korean literature on FXS. To the best of our knowledge,
this is the first report on the use of MS-PCR for the diagno-
sis of FXS. In FXS, there are two special subclasses of mosai-
cism based on the size and methylation status. Size mosaics
occur in those patients with both full mutation and premu-
tation, a pattern that is detected in about 25% of male and
in less than 10% of female patients. Methylation mosaics
are those with variations between cells in the methylation
status of a full mutation. The proportion of leucocytes with
an unmethylated full mutation may vary from low (approx-
imately 10%) to 100% (19, 20). Therefore, the use of MS-
PCR in the molecular diagnosis of FXS should be comple-
mented with the PCR and Southern blotting due to methy-
lation mosaicism as well as size mosaicism of the FMR1.
FXS has been found in many populations throughout the
world. Many studies on the prevalence of FXS were carried
out in the past by cytogenetic analysis (21), and similar stud-
ies are now being undertaken using DNA analysis. Never-
theless, there is relatively a few published on DNA-based
FXS screening among different ethnic groups. The preva-
lence of FXS, based on DNA analysis of population samples,
has been reported as 1/4,000 males and 1/6,000-8,000 females
in western countries (22). Crawford et al. reported a higher
point estimate of FXS for African-American males (1/2,545;
95% confidence interval [CI], 1/5,208-1/1,289) than reported
previously, although CI include the prevalence for Caucasians
Authors Diagnostic methods  Study subjects Main findings
Year of 
publication
Yim This study MS-PCR, PCR &  65 children referred for the diagnosis 4 cases of full mutation (6.15%)
Southern blotting of fragile X syndrome and 1 case of premutation
Hur (10) 2003 PCR & Southern blotting 83 women with idiopathic premature 3 cases of premutation (3.61%)
ovarian failure
Song (18) 2002 PCR 1,000 low risk women Mean number of CGG: 
26.9 repeats
Kwon (13) 2001 PCR & Southern blotting 101 children with mental retardation 1 case of full mutation (0.99%)
Kim (12) 2001 PCR & Southern blotting Prenatal diagnosis for a mother with premutation Fetus with full mutation
Park (16) 1999 PCR 699 neonates 3 cases with premutation (0.43%)
Kang (11) 1999 Southern blotting 66 autistic children 1 case of size mosaicism 
(full mutation/premutation; 1.64%)
5 cases of premutation 
Hong (8) 1999 Cytogenetic study 604 child psychiatry patients 5 children with fragile X 
syndrome (0.83%)
Choi (6) 1999 Cytogenetic, PCR &   212 children with mental retardation 6 cases of full mutation (2.83%)
Southern blotting
Hong (9) 1998 Southern blotting 122 children with PDD 2 cases of full mutation (1.64%)
Chung (7) 1997 PCR & Southern blotting 7 children  3 cases of full mutation
4 cases of premutation
Lee (14) 1995 PCR & Southern blotting 94 cases referred for diagnosis  8 case of full mutation (8.51%)
of fragile X syndrome 9 cases of premutation
Shin (17) 1994 Cytogenetic study 259 children with mental retardation 2 cases of fragile X 
syndrome (0.77%)
Moon (15) 1993 Cytogenetic study 153 boys with mental retardation of  Positive for fra(X) in 10 boys (6.54%)
unknown etiology
Table 2. Review of the literature on fragile X syndrome published in Korea
PCR, polymerase chain reaction; PDD, pervasive developmental disorder.474 S.-Y. Yim, B.H. Jeon, J.A. Yang, et al.
estimated from this (1/3,717; 95% CI, 1/7,692-1/1,869)
(23). With regard to the prevalence of FXS, there is always
the possibility that founder effects (the founding group hav-
ing an overrepresentation of relatively unstable alleles in the
intermediate or premutation range) could result in some pop-
ulations having a higher prevalence of FXS. 
Through the molecular diagnosis, Goldman et al. found
FXS in 6.1% of 148 mentally retarded, black South African
males (24), which is similar to our result. In Asia, Arinami
et al. reported 8.6% of the positive rate of FXS among 152
male inmates population with unknown causes of mental
retardation (25). In 1995, Lee et al. reported 8 cases of FXS
(8.5%), and 9 cases of premutation (9.6%) out of 94 cases
referred for the diagnosis of FXS in Korea, using the molecu-
lar diagnosis (14). According to the literature review, although
there has yet been population-based prevalence study pub-
lished in Korea, the positive rate of FXS appears to be in the
range of 0.77-8.51% (6, 8, 9, 11, 13-15, 17), depending on
the study subjects and the diagnostic methods. Therefore, this
information does not seem to allow any conclusion on the
prevalence of FXS among Korean population. 
In FXS, the transition from unmethylated moderate expan-
sions of the CGG repeat (premutations) to methylated large
expansions (full mutations) occurs only through maternal
transmission. The timing of this transition was the subject
of much speculation. Based on the observation that males
with full mutation have premutation in sperm, a postzygot-
ic transition was proposed as a preferred model. The risk of
such transition is highly correlated with the size of the mater-
nal premutation, being very low for small PM alleles (≤60
repeats) and 100% for alleles above 100 repeats. The Amer-
ican College of Medical Genetics (ACMG) in 2001 defined
the lower bound of the premutation range at 55 CGG repeats,
irrespective of nucleotide composition of the repeat sequence
(5). The positive rate of premutation alleles >54 repeats in
the general population is estimated at 1/259 females and
1/813 males (26). Smaller CGG repeats (~45-54 repeats)
can also be associated with repeat length instability upon
transmission, with the possibility of expanding to a full muta-
tion. It has been reported that the smallest premutation alle-
les that expanded to a full mutation (>200 repeats) in one
generation contained 59 repeats with no AGG interruptions
within the FMR1 CGG repeat (27). In terms of premuta-
tion, besides the number of CGG repeats, the number of
AGG interruptions within the CGG tract also plays a role
in repeat-length stability (27). There is some evidence to indi-
cate that the instability in both meiosis and mitosis depends
critically on the length of pure CGG tracts within the 3’ end
of the array. The majority of FMR1 alleles have the CGG
tract interrupted by regularly interspersed AGG triplets;
every 10th, 11th, or 12th CGG repeat unit. Most FMR1
alleles are likely to be stable because either the total repeat
length is less than 34 or there are sufficient interspersed AGGs
to keep the pure 3’ CGG tract below the 34 threshold. In
vitro studies have shown that AGGs within a CGG tract
can prevent the formation of the stable hairpin structures
implicated in the replication slippage that is probably the
immediate cause of the expansion (19). From the practical
point of view, the distinction of normal-size alleles, inter-
mediate-size alleles, and lower end of premutation seems to
be not always clear, and it may be due to technical sensitivi-
ty as well as the presence of family history and repeat insta-
bility. 
Although patients with FXS suffer from profound to bor-
derline mental retardation, the presence of a methylated full
mutation is routinely associated with their cognitive dysfunc-
tion. Nevertheless, no correlation is observed between the
degree of MR and the size of the full mutation. The expan-
sion size does not necessarily have an influence on the sever-
ity of the clinical phenotype in the males, presumably because
hypermethylation of the FMR1 gene at a particular repeat-
size threshold produces an ‘all or none’ effect. To the best of
our knowledge, it is not clear whether the normal size alle-
les of FMR1 can produce functional FMRP or not, in the
mosaics of full mutation/normal size alleles of FMR1. Fur-
ther study on the assessment of FMRP level is required. In
our case series of FXS, there was one mother with full muta-
tion and 3 mothers with premutation of FMR1. Although
the psychological evaluations for those mothers were not
done, these mothers were regular high school or college grad-
uates and denied any learning problems. Case 3 reported to
have three maternal cousins with mental retardation. It is
generally known that about 50% of heterozygous females
with full mutation have some degree of learning difficulties
due to inactivation of one of the X chromosomes (19). 
In our case series, there was one boy with premutation
who showed severe clinical presentations indistinguishable
from boys with full mutation. He had premutation with 58
CGG repeats, which was thought to be relatively low copy
number. Besides the clinical effects of premutation in adults
such as premature ovarian failure and fragile-X associated
tremor ataxia syndrome (FXTAS), several studies show the
presence of neurobehavioral symptoms in children (28). Esch
identified several boys with premutation with learning prob-
lems, developmental delay and/or autistic features, and she
identified four times more premutations in the group of boys
younger than 16 yr old with developmental problems who
were referred for FMR1 testing. Although larger and more
longitudinal standardized studies are needed, these data
provide further evidence that fragile X premutations may
affect neurocognitive and behavioral functioning in children
(29). Tassone et al. found lowered FMRP levels in some chil-
dren with premutation who presented with mental retarda-
tion and/or autism, suggesting a spectrum of clinical severi-
ty associated with related protein deficit (30). Similar obser-
vation has also been reported in 5 children with diagnosis of
autistic spectrum disorder and premutation (31). However,
whether his clinical features including mental retardationFragile X Syndrome in Korea  475
and behavioral problems were related with his premutation
of FMR1 or not is inconclusive at this point.
In our case series, the mean age at the diagnosis of FXS or
premutation of FMR1 was 4.28 yr (range; 1.2-9.9 yr old).
Most of Down syndrome cases are identified at birth on the
basis of physical features; however, FXS is not at all obvious
at birth. Usually, parents begin to notice behavioral prob-
lems or delayed attainment of developmental milestones.
Sometimes, these signs are subtle and it may take a long
time for a physician or other professional to acknowledge
that a problem exists. Early identification of FXS remains
important not only for genetic counseling and prenatal test-
ing, but also for parents and children to explain their diffi-
culties, thereby facilitating the access to educational and
clinical services.
In our case series, brain MRI findings were not remark-
able. Although brain weight and gross anatomy in FXS have
been reported to be normal, there is, however, mounting
evidence of morphological abnormalities of the brain in the
FXS. Several structural MRI studies have reported reduced
cerebellar vermis size and enlarged fourth ventricle in FXS
individuals. An increase in caudate nucleus volume has been
found in children with FXS (32, 33). 
Several limitations are noted in our current study, mainly
due to its retrospective nature. Regardless of these limita-
tions, however, it is believed that this case series might be
able to add some valuable information to the body of knowl-
edge of FXS in Korea.
In summary, we presented four cases of FXS and one case
of premutation with their clinical characteristics with a
review of the literature. 
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